CG Oncology, Inc. Common stock (CGON) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Irvine, DE, United States. El CEO actual es Arthur Kuan.
CGON tiene fecha de IPO 2024-01-25, 113 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.68B.
CG Oncology Inc is a clinical biopharmaceutical company developing innovative therapies for bladder cancer treatment. The company's lead product candidate, cretostimogene, is designed as a bladder-sparing therapeutic in clinical development for high-risk non-muscle invasive bladder cancer patients who have failed to respond to BCG immunotherapy, the current standard treatment. CG Oncology aims to address a significant unmet medical need in oncology by offering an alternative treatment option for BCG-unresponsive patients and positioning cretostimogene as a potential backbone therapy for bladder cancer management.
